sarcoidosis%20-%20pulmonary
SARCOIDOSIS - PULMONARY
Sarcoidosis is a multisystem disease which may present with non-specific symptoms or symptoms related to organ-specific involvement.
Non-specific symptoms include fever, malaise, fatigue and weight loss.
Pulmonary involvement is seen in >90% of sarcoidosis patients.

Follow Up

General Surveillance Principles

  • Sarcoidosis patients should be monitored regularly
  • Monitoring should include a review of symptoms, physical exam, CXR & lung function tests
    • Perform other tests as necessary based on organ involvement
  • Monitor & treat patients for complications of sarcoidosis & related conditions (eg aspergilloma, osteoporosis, hypercalcemia, hypercalciuria)
  • Patients who have undergone therapy should be monitored for 3 years after cessation of treatment
  • Intermittent monitoring (every 3-6 months) is recommended for patients on TNF-alpha inhibitor therapy

Monitoring Intervals Based on Disease Stage

Stage 1

  • Initially every 6 months then once a year if stable

Stage 2, 3, 4

  • Initially every 3-6 months; monitor indefinitely

Serious extrapulmonary involvement, regardless of radiographic stage

  • Monitor indefinitely
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 22 Aug 2018
Fast food consumption appears to be detrimental to health, with hamburgers having been shown to have a dose-response association with the risk of asthma.
Roshini Claire Anthony, 05 Sep 2018

Patients admitted to the intensive care unit (ICU) with severe influenza have an elevated risk of developing invasive pulmonary aspergillosis, particularly if they are immunocompromised at time of admission, a recent study has shown.

Radha Chitale, 06 Apr 2016
An investigational device monitoring fluid accumulation in the lungs significantly reduced hospitalization due to heart failure and death by any cause among heart failure patients compared with standard monitoring and treatment methods, according to results from the IMPEDANCE-HF trial reported during the recent ACC meeting in Chicago, Illinois, US.